Bayer AG http://www.alacrastore.com/company-snapshot/Bayer_AG-1001897 Friday, July 25, 2008 11:30:53 PM 1001897 Bayer AG en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0005-26537288newstex/PRN-0005-26537288xml WHITE PLAINS, N.Y., Jul. #, #### (PRNewswire delivered by Newstex) -- The following release was issued today by Thomas M. Skelton and Richard W. Cohen of Lowey Dannenberg Cohen& Hart, P.C.: UNITED STATES DISTRICT COURT SOUTHERN DISTRICT...02000000020020000200200402002006020020050400000004016000040160277/9/2008 10:20:16 AM1800000018014000190000001900100019001032PR Newswire USPRN-0005-26537288BAYER AKTIENGESELLSCHAFTBAYNewsNewstexCHINA - Bayer Healthcare AG, a majority-owned unit of Bayer AG, acquired the cough & cold portfolio of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co Ltd, a pharmaceutical products manufacturer, for #.### bil Chinese yuan (###.### mil euros/$###.### mil US). The consideration consisted of #.### bil yuan (##.### mil euros/$###.### mil) and up to ### mil yuan (##.## mil euros/$##.### mil) in profit-related payments. The transaction was subject to regulatory approvals.7/4/2008 11:06:14 AM07287J89083W07273089081MBayer Healthcare AGTopsun Science & Technology Qidong Gaitianli Pharm-Cough & Cold PortfolioBayer AGTopsun Science & Technology Qidong Gaitianli Pharmaceuticalhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Bayer_Healthcare_AG_acquires_Topsun_Science_Portfolio_from_Topsun_Science_Tech_Qidong-1992966040sdc/19929660401992966040Copyright © 2008, Thomson Financial, All Rights ReservedDrugsGermanyPharmaceutical preparations2834FFForeignSubsidiary2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2821:Plastics materials and synthetic resins2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec2899:Chemicals and chemical preparations, necDrugsChinaPharmaceutical preparations2834FFForeignSubsidiary883873001Mnfr,whl pharmaceuticalsMnfr pharm prodCashEarnoutAssets1026820001Jul 4 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.00000Bayer HealthCare AG, locatedin Leverkusen, Germany,manufactures pharmaceuticalproducts focused on productsthat diagnose, prevent, andtreat disease of both humansand animals worldwide. Theyhave four divisions: AnimalHealth (veterinary drugs);Consumer Care (OTC meds);Diabetes Care; andPharmaceuticals (representedby Bayer-Schering Pharma andBayer HealthcarePharmaceuticals), operating inmore than 120 countriesworldwide. The company wasfounded in 1863.Bayer HealthCare AG, located in Leverkusen, Germany,manufactures pharmaceutical products focused on productsthat diagnose, prevent, and treat disease of both humans andanimals worldwide. They have four divisions: Animal Health(veterinary drugs); Consumer Care (OTC meds); Diabetes Care;and Pharmaceuticals (represented by Bayer-Schering Pharmaand Bayer Healthcare Pharmaceuticals), operating in morethan 120 countries worldwide. The company was founded in1863.Bayer HealthCare AG, located in Leverkusen, Germany, manufactures pharmaceutical products focused on products that diagnose, prevent, and treat disease of both humans and animals worldwide. They have four divisions: Animal Health (veterinary drugs); Consumer Care (OTC meds); Diabetes Care; and Pharmaceuticals (represented by Bayer-Schering Pharma and Bayer Healthcare Pharmaceuticals), operating in more than 120 countries worldwide. The company was founded in 1863.1.000002.000003.000004.000005.000006.000007.00000The Cough & Cold Portfolio ofTopsun Science & TechnologyQidong GaitianliPharmaceutical Co Ltd includesthe brand White & Black,personnel and assets relatedto the business.The Cough & Cold Portfolio of Topsun Science & TechnologyQidong Gaitianli Pharmaceutical Co Ltd includes the brandWhite & Black, personnel and assets related to the business.The Cough & Cold Portfolio of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co Ltd includes the brand White & Black, personnel and assets related to the business.0.000000.000000.000000.00000YChinese Yuan02 Jul 08Wed, 02 Jul 2008 00:00:00 ESTDate Announced: 07/02/200802 Jul 08Date Effective: 07/02/200802 Jul 08Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.000001264 Chinese Yuan1264.000000.000001264 Chinese Yuan1264.00000100.00000100.000000.000000.000001264.000001264 Chinese Yuan0.14600N92.674000.000000.000000.000000.000000.00000184.69100184.691000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.00000CHINA - Bayer Healthcare AG, amajority-owned unit of BayerAG, acquired the cough & coldportfolio of Topsun Science &Technology Qidong GaitianliPharmaceutical Co Ltd, apharmaceutical productsmanufacturer, for 1.264 bilChinese yuan (116.263 mileuros/$184.691 mil US). Theconsideration consisted of1.072 bil yuan (98.603 mileuros/$156.636 mil) and up to192 mil yuan (17.66 mileuros/$28.054 mil) inprofit-related payments. Thetransaction was subject toregulatory approvals.CHINA - Bayer Healthcare AG, a majority-owned unit of Bayer AG, acquired the cough & cold portfolio of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co Ltd, a pharmaceutical products manufacturer, for 1.264 bil Chinese yuan (116.263 mil euros/$184.691 mil US). The consideration consisted of 1.072 bil yuan (98.603 mil euros/$156.636 mil) and up to 192 mil yuan (17.66 mil euros/$28.054 mil) in profit-related payments. The transaction was subject to regulatory approvals.CHINA - Bayer Healthcare AG, a majority-owned unit of Bayer AG, acquired the cough & coldportfolio of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co Ltd, apharmaceutical products manufacturer, for 1.264 bil Chinese yuan (116.263 mileuros/$184.691 mil US). The consideration consisted of 1.072 bil yuan (98.603 mileuros/$156.636 mil) and up to 192 mil yuan (17.66 mil euros/$28.054 mil) in profit-relatedpayments. The transaction was subject to regulatory approvals.CHINA - Bayer Healthcare AG, a majority-owned unit of Bayer AG, acquired the cough & cold portfolio of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co Ltd, a pharmaceutical productsmanufacturer, for 1.264 bil Chinese yuan (116.263 mil euros/$184.691 mil US). The consideration consisted of 1.072 bil yuan (98.603 mil euros/$156.636 mil) and up to 192 mil yuan (17.66 mileuros/$28.054 mil) in profit-related payments. The transaction was subject to regulatory approvals.CHINA - Bayer Healthcare AG, a majority-owned unit of Bayer AG, acquired the cough & cold portfolio of Topsun Science & Technology QidongGaitianli Pharmaceutical Co Ltd, a pharmaceutical products manufacturer, for 1.264 bil Chinese yuan (116.263 mil euros/$184.691 mil US).The consideration consisted of 1.072 bil yuan (98.603 mil euros/$156.636 mil) and up to 192 mil yuan (17.66 mil euros/$28.054 mil) inprofit-related payments. The transaction was subject to regulatory approvals.Completed0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Completed-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances100861001FrankfurtGermany2833ForeignPublicBAY2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances1026816001China2834ForeignPrivate184.691001264.00000184.6910092.67400Deal InformationThomson Financial Mergers & AcquisitionsUS - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company, for $### mil. The consideration was to consist of $## mil and up to $## mil in profit-related payments.7/3/2008 11:02:13 AM07287J57822W072730577776Bayer Healthcare AGMaxygen Inc-Haemophilia Programme AssetsBayer AGMaxygen Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Bayer_Healthcare_AG_acquires_Maxygen_Inc_Haemophilia_from_Maxygen_Inc-1992780020sdc/19927800201992780020Copyright © 2008, Thomson Financial, All Rights ReservedDrugsGermanyPharmaceutical preparations2834FFForeignSubsidiary2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2821:Plastics materials and synthetic resins2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec2899:Chemicals and chemical preparations, necDrugsUnited StatesBiological products, except diagnostic substances2836CACaliforniaSubsidiary883873001Mnfr,whl pharmaceuticalsBiotech coCashEarnoutAssets1026702001Jul 3 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.00000Bayer HealthCare AG, locatedin Leverkusen, Germany,manufactures pharmaceuticalproducts focused on productsthat diagnose, prevent, andtreat disease of both humansand animals worldwide. Theyhave four divisions: AnimalHealth (veterinary drugs);Consumer Care (OTC meds);Diabetes Care; andPharmaceuticals (representedby Bayer-Schering Pharma andBayer HealthcarePharmaceuticals), operating inmore than 120 countriesworldwide. The company wasfounded in 1863.Bayer HealthCare AG, located in Leverkusen, Germany,manufactures pharmaceutical products focused on productsthat diagnose, prevent, and treat disease of both humans andanimals worldwide. They have four divisions: Animal Health(veterinary drugs); Consumer Care (OTC meds); Diabetes Care;and Pharmaceuticals (represented by Bayer-Schering Pharmaand Bayer Healthcare Pharmaceuticals), operating in morethan 120 countries worldwide. The company was founded in1863.Bayer HealthCare AG, located in Leverkusen, Germany, manufactures pharmaceutical products focused on products that diagnose, prevent, and treat disease of both humans and animals worldwide. They have four divisions: Animal Health (veterinary drugs); Consumer Care (OTC meds); Diabetes Care; and Pharmaceuticals (represented by Bayer-Schering Pharma and Bayer Healthcare Pharmaceuticals), operating in more than 120 countries worldwide. The company was founded in 1863.1.000002.000003.000004.000005.00000The Haemophilia programmeassets of Maxygen Inc, locatedin California, which treatsblood-clotting disorderhaemophilia.The Haemophilia programme assets of Maxygen Inc, located inCalifornia, which treats blood-clotting disorderhaemophilia.The Haemophilia programme assets of Maxygen Inc, located in California, which treats blood-clotting disorder haemophilia.0.000000.000000.000000.00000YU.S. Dollar02 Jul 08Wed, 02 Jul 2008 00:00:00 ESTDate Announced: 07/02/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.00000120 U.S. Dollar120.000000.00000120 U.S. Dollar120.000000.000000.000000.000000.00000120.00000120 U.S. Dollar1.00000N60.214000.000000.000000.000000.000000.00000120.00000120.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.00000US - Bayer Healthcare AG, aunit of Bayer AG, agreed toacquire the Haemophiliaprogramme assets of MaxygenInc, a biotechnology company,for $120 mil. Theconsideration was to consistof $90 mil and up to $30 milin profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company, for $120 mil. The consideration was to consist of $90 mil and up to $30 mil in profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programmeassets of Maxygen Inc, a biotechnology company, for $120 mil. The consideration was toconsist of $90 mil and up to $30 mil in profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company, for $120 mil. The consideration was to consist of $90 mil andup to $30 mil in profit-related payments.US - Bayer Healthcare AG, a unit of Bayer AG, agreed to acquire the Haemophilia programme assets of Maxygen Inc, a biotechnology company,for $120 mil. The consideration was to consist of $90 mil and up to $30 mil in profit-related payments.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations100861001FrankfurtGermany2833ForeignPublicBAY2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations617238002NasdaqUnited States2836CaliforniaPublicMAXY120.00000120.00000120.0000060.21400Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/cs/71227cs/71227norm Ethylene - Energy Shock Feedstock costs continued its unremitting rise in June, as weighted average cash cost increased #.##¢/lb or ##.#% to ##.##¢lb in the month.    Ethane costs surged ##.#% to ##.##¢/lb in June, as the increased...712271185YesD0Article9881107961491877111151166715251615058311416661346533182413691471174976248148corp/reportshycorp39542High Yield7/2/2008 10:05:12 PM150Ethane costs surged 24.6% to 55.02¢/lb in June, as the increased ethane cracking production and the incremental demand pull from cracker restarts have contributed to lower ethane inventory levels and tightening of fundamentals.71227Credit & Investment ResearchCreditSightsAUSTRALIA - Cheminova Agro A/S, a unit of Auriga Industries A/S, signed a Letter of Intent {LoI} to acquire the formulation and filling facility, located in Wyong, New South Wales, of Bayer Cropscience AG, a unit of Bayer AG. Terms were not disclosed.6/24/2008 2:23:15 PM16381M07292E05149A072730Cheminova Agro A/SBayer Cropscience AG- Formulation & Filling Facility ,Wyong,NSWAuriga Industries A/SBayer AGhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Cheminova_Agro_A_S_acquires_Bayer_Cropscience_Facility_NSW_from_Bayer_AG-1989202040sdc/19892020401989202040Copyright © 2008, Thomson Financial, All Rights ReservedChemicals and Allied ProductsDenmarkPesticides and agricultural chemicals, nec2879FFForeignSubsidiary2879:Pesticides and agricultural chemicals, nec2819:Industrial inorganic chemicals, nec2879:Pesticides and agricultural chemicals, nec2899:Chemicals and chemical preparations, nec3312:Steel works, blast furnaces, and rolling mills3331:Primary smelting and refining of copper3339:Primary nonferrous metals, except copper, aluminumChemicals and Allied ProductsAustraliaNitrogenous fertilizers2873FFForeignSubsidiary223049001Mnfr inorganic chemicalsMnfr,whl pharmaceuticalsUnspecifiedAssets1024234001Jun 24 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.00000Cheminova Agro A/S, located inLemvig, manufacturespesticides. The company wasfounded on December 31, 1938.Cheminova Agro A/S, located in Lemvig, manufacturespesticides. The company was founded on December 31, 1938.Cheminova Agro A/S, located in Lemvig, manufactures pesticides. The company was founded on December 31, 1938.1.000002.000003.000004.000005.000006.00000A formulation and fillingfacility of Bayer CropScienceAG, an agricultural chemicalsmanufacturer and wholesaler.The facility is located inWyong, New South WalesA formulation and filling facility of Bayer CropScience AG,an agricultural chemicals manufacturer and wholesaler. Thefacility is located in Wyong, New South WalesA formulation and filling facility of Bayer CropScience AG, an agricultural chemicals manufacturer and wholesaler. The facility is located in Wyong, New South Wales0.000000.000000.000000.00000Y20 Jun 08Fri, 20 Jun 2008 00:00:00 ESTDate Announced: 06/20/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.000000.000000.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.00000AUSTRALIA - Cheminova AgroA/S, a unit of AurigaIndustries A/S, signed aLetter of Intent {LoI} toacquire the formulation andfilling facility, located inWyong, New South Wales, ofBayer Cropscience AG, a unitof Bayer AG. Terms were notdisclosed.AUSTRALIA - Cheminova Agro A/S, a unit of Auriga Industries A/S, signed a Letter of Intent {LoI} to acquire the formulation and filling facility, located in Wyong, New South Wales, of Bayer Cropscience AG, a unit of Bayer AG. Terms were not disclosed.AUSTRALIA - Cheminova Agro A/S, a unit of Auriga Industries A/S, signed a Letter of Intent{LoI} to acquire the formulation and filling facility, located in Wyong, New South Wales,of Bayer Cropscience AG, a unit of Bayer AG. Terms were not disclosed.AUSTRALIA - Cheminova Agro A/S, a unit of Auriga Industries A/S, signed a Letter of Intent {LoI} to acquire the formulation and filling facility, located in Wyong, New South Wales, of BayerCropscience AG, a unit of Bayer AG. Terms were not disclosed.AUSTRALIA - Cheminova Agro A/S, a unit of Auriga Industries A/S, signed a Letter of Intent {LoI} to acquire the formulation and fillingfacility, located in Wyong, New South Wales, of Bayer Cropscience AG, a unit of Bayer AG. Terms were not disclosed.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002819:Industrial inorganic chemicals, nec2869:Industrial organic chemicals, nec2873:Nitrogenous fertilizers2874:Phosphatic fertilizers2875:Fertilizers, mixing only2879:Pesticides and agricultural chemicals, nec708292001CopenhagenDenmark2819ForeignPublicAURIB2821:Plastics materials and synthetic resins2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2879:Pesticides and agricultural chemicals, nec2899:Chemicals and chemical preparations, nec100861001FrankfurtGermany2833ForeignPublicBAY0.000000.000000.000000.00000Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/cs/70643cs/70643norm Trends In Chems: #Q## Review - Economy & Energy Pack One-Two Punch The chemicals sector inaugurates the New Year with solid #Q## results, highlighted by aggregate sales increase and EBITDA gains of ##.#% and ##.#% year-over-year for...706439525YesD0Article110988112705187714911113567961515831511166711805169401501521369182416665331355117313461451142481174148976147corphycorp/reports39542High Yield68Earnings Reports - Industrials/Consumer6/20/2008 2:14:50 AM150With the one-two punch of a slowing economy and rising energy costs, it remains to be seen whether companies will be able recover margins in the coming quarters.70643Credit & Investment ResearchCreditSightshttp://www.alacrastore.com/storecontent/fitch/424185_pr_framefitch/424185_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.AstraZeneca plcBayer AGGlaxoSmithKline plcNovartis AGRoche Deutschland Holding GmbHSanofi-Aventis S.A.8036243480457972804579768045797980457983858840736/18/2008 10:18:00 AM0100000001030000010317000103170385Press ReleaseAZNBAYGSKNOVNSAN424185_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/cs/54231cs/54231norm Ethylene - Strong, But For How Long? The ethylene market strengthened in March, and momentum is carrying into April. The expansion will likely to be exaggerated by lean inventories, rising prices, and exports, which continue to be...16661369134618249762481174114147148corp/reportscorp542High Yield6/17/2008 12:05:37 PM150The ethylene market strengthened in March, and momentum is carrying into April. However, given our outlook for residential construction and auto production, we remain concerned about the duration of the expansion.542311371YesD0Article1119881101521491877583151166779651615053354231Credit & Investment ResearchCreditSightshttp://www.alacrastore.com/storecontent/fitch/423081_pr_framefitch/423081_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Abbott LaboratoriesAstraZeneca plcBayer AGFresenius SEGlaxoSmithKline plcMerck & Company, Inc.Novartis AGPfizer Inc.Roche Deutschland Holding GmbHSanofi-Aventis S.A.Wyeth8009174080360516803613728036159280361630803624348045797280457976804579798045798382151338858840736/9/2008 2:13:00 PM010000000103000001031700010317030104000085Press ReleaseABTAZNBAYFREGSKMRKNOVNPFESANWYE423081_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25776581newstex/PRN-0005-25776581xml CHICAGO, Jun. #, #### (PRNewswire delivered by Newstex) -- Thirteen-year old Andrey Velizarow Simeonovski, a fifth-grader at Chase Elementary School, and seven-year old Patrick Lambe, a first-grader from St. Monica's Academy, were named...0600000006004000060110001700000017002000050000000500500004000000040180000800000008006000110000001101400006005000060050010600500206005004060020000600200203000000030020000300200313000000130040001300400513001000130010040401600004016013140000001402400014024001010000000100100001001001080030006/5/2008 8:23:31 AM18000000180150001801600018022000190000001900100019001013PR Newswire USPRN-0005-25776581BAYER AKTIENGESELLSCHAFTBAYNewsNewstexhttp://www.alacrastore.com/storecontent/moodys/PR_156612_95545moodys/PR_156612_95545htmlGlobal Credit Research Rating Action # JUN #### Rating Action: Bayer Capital Corporation B.V. Moody's changes outlook on Bayer's ratings to stable. London, ## June #### -- Moody's Investors Service has today changed the outlook to...6/4/2008 1:52:09 AMhtmlBayer Capital Corporation B.V.Bayer AGBayer Holding Japan LLCBayer CorporationBayer AG; Bayer Capital Corporation B.V.; Bayer Corporation; ...9554595527820142128600009550150.0000NewsRating ActionPR_156612_95545Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/cs/70184cs/70184norm Ethylene - Spring Low Lullaby While producers were able to raise prices with average acquisition price increasing #.##¢/lb in the last two months, feedstock costs outpaced prices increases, as average acquisition margins declined #.##¢/lb...701841291YesD0Article9881107961491877111151166715251615058311416661346533182413691471174976248148corp/reportshy39542High Yield6/3/2008 11:06:00 PM150We look at reasons for the weakness in the ethylene market, outline some of the risks inherent in the current market conditions, and examine historical profitability of Equistar and Nova Chemicals against ethylene cash margins.70184Credit & Investment ResearchCreditSightshttp://www.alacrastore.com/storecontent/newstex/PRN-0001-25693165newstex/PRN-0001-25693165xml /CNW Telbec/ -- New data presented this weekend at the ##th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago show RAD### *(everolimus) may provide an important new treatment option for patients with advanced...0700000007005000070010000700100407014000070140080701401207003000070030010400000004002000040020060400600004006005040160000401603113000000130010001300100213010000130100056/2/2008 11:17:04 AM1800000018018000190000001900200019002012Canada NewsWire GroupPRN-0001-25693165BAYER AKTIENGESELLSCHAFTGENENTECH INCNOVARTIS AGPFIZER INCBAYDNANVSPFENewsNewstexhttp://www.alacrastore.com/storecontent/fitch/387042_report_framefitch/387042_report_framepdfFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Bayer AG858840735/20/2008 10:18:00 AM010000000103000001031700165Credit UpdateBAY387042_report_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/fitch/421007_pr_framefitch/421007_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Bayer AG80360516858840735/20/2008 10:18:00 AM01000000010300000103170085Press ReleaseBAY421007_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/newstex/MW-0001-25290591newstex/MW-0001-25290591xml LONDON, UNITED KINGDOM, May ##, #### (Marketwire delivered by Newstex) -- Reportlinker.com announces that a new market research report related to the Plastic industry is available in its catalogue. World Foamed Plastics (Polyurethane)...0400000004018000100000001000900004002000040020070401600004016013040110000401100204013000040130031300000013004000130040015/15/2008 6:22:34 AM18000000180220001801500018020000190000001900100019002000190020041900200919002013190020071900201219002018MarketwireMW-0001-25290591BAYER AKTIENGESELLSCHAFTDOW CHEMICAL COFOAMEX INTERNATIONAL INC.HUNTSMAN CORPBAYDOWFMXLHUNNewsNewstexhttp://www.alacrastore.com/storecontent/cs/56121cs/56121norm Trends in Chems: #Q## - Mild Spring The seasonal recovery continues despite continued weakness in some end markets. In base chemicals, a rebound began in March and continues to unfold, but prices and volumes remain below year-ago levels....533166618241173145134611742481877149976147148bscore/researchcorp/reportshycorp55/14/2008 11:06:25 AM250The seasonal recovery continues despite continued weakness in some end markets. We continue to see the best of times in the prolonged chemical cycle as behind us but don't expect a rapid deterioration in 2007.5612114725YesD8BondScore7051127961101356111988516151166715115831180150940136956121Credit & Investment ResearchCreditSightshttp://www.alacrastore.com/storecontent/cs/61531cs/61531norm Ethylene: A Not So Merry Christmas for Producers While our base petrochemical names had a relatively healthy #Q## of earnings, the fourth quarter may see producers finding coal in their stocking.  Rising commodity prices have played...1505831141666134653318241369988615311039YesD0Article516150While our base petrochemical names had a relatively healthy 3Q07 of earnings, the fourth quarter may see producers finding coal in their stocking.110796149187711115116671521471174976248148corp/reportscorphy39542High Yield5/14/2008 10:08:48 AM61531Credit & Investment ResearchCreditSightshttp://www.alacrastore.com/storecontent/newstex/PRN-0003-25085020newstex/PRN-0003-25085020xml SAN FRANCISCO and NEW YORK, May #, #### (PR Newswire Europe delivered by Newstex) -- - NGN Capital leads US$## Million in Series A First Tranche Financing NGN Capital announced today the formation of ACT Biotech Inc., a new company...04000000040180000900000009015000040020000400200104006000040060050401600004016008130000001301000013010005070000000701400007014008070010000700100407003000070030015/7/2008 1:21:26 PM1800000018022000190000001900100019001032190010051900200019002013PR Newswire EuropePRN-0003-25085020BAYER AKTIENGESELLSCHAFTBAYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25083005newstex/PRN-0005-25083005xml SAN FRANCISCO and NEW YORK, May #, May #, #### (PR Newswire delivered by Newstex) -- SAN FRANCISCO and NEW YORK, May # /PRNewswire/ -- NGN Capital announced today the formation of ACT Biotech Inc., a new company dedicated to developing...0400000004018000090000000901500004002000040020010400600004006005070000000701400007014008070010000700100407003000070030011300000013010000130100055/7/2008 12:23:26 PM1800000018022000190000001900100019001005190010321900200019002013PR Newswire USPRN-0005-25083005BAYER AKTIENGESELLSCHAFTBAYNewsNewstex